drugset
drugset / Trial / NCT03738111

Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma

NCT03738111 ↗

Phase 1 Withdrawn Lee's Pharmaceutical Limited China Oncology Focus Limited · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single-centre, open-label, dose escalation, Phase 1 study. The primary objective is to determine the highest dose of TG02 citrate that can safely be given to patients with advanced hepatocellular carcinoma.

Timeline

Start
2018-12
Primary completion
2021-08
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Zotiraciclib Small molecule — Oral

Indications

hepatocellular carcinoma